2026 Q2 - tulosraportti
35 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 44 | - | - | ||
| 7 000 | - | - | ||
| 233 | - | - | ||
| 1 200 | - | - | ||
| 1 200 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
7 min sittenStay Tuned
Now you are probably looking to provoke "the phantom" on the forum here🫣🤣 Fingers crossed, some lose their breath from such☠️🤣 I am popping popcorn🍿🍿
·29 min sittenWe are just about in the most exciting and critical period for Circio, so it is probably not surprising that the stock does not dip like we see among several other biotechs right now (mostly due to the ten-year yield?). I believe the yield can speed up deals due to fear of missing out in the field, but that it can also go the other way. The only thing that matters now in my opinion is data releases which most likely will come on 27 October (ESGCT), and possibly in November. Conferences are not price-driving in themselves as long as they do not coincide with new data or a new deal. When in vivo in CNS is available, and if good data, we will hopefully soon see an up-front with BF. Then we will in that case guaranteed see a repricing. That is supposedly predicted to come at the end of '26 or sometime in H1 '27 (if everything goes according to plan). Car-t data will be price-driving, eye and heart as well, but everything still takes time, and 2027 could be the year things happen. And we can also hope for a positive surprise in addition to what we know and can relate to (not acquisitions, but deals). I believe a little patience will pay off anyway. That is if this goes the way most of us think. Please correct me. Go Circio🥳
·31 min sittenRegarding the use of the 200 million. - The delivery issues were identified long before September. The Acuitas partnership was announced as early as 15 April. The September share issue therefore provides financing to continue and expand an existing strategy. - The 200 million is also research capital. The funds will finance testing and selection of DNA vectors and delivery technology, as well as secure access to what works best. The entire amount is not an acquisition reserve. - A license can be the most important transaction. Circio does not need to own the supplier if the agreement grants sufficient commercial rights to the technology. The value will depend on, among other things, applications, potential exclusivity, sublicensing, and future payments. The most interesting question is therefore what rights Circio can secure. If the company combines circVec with a suitable DNA vector and good T-cell delivery, documents the function and secures attractive rights, it can provide a more complete offering to future industrial partners. Phoenix fits well into this strategy.
50 min sittenShorters still here? Where i can see them?
They are not shorting now. The last short became visible/set 15.09 the same date as the issue came at 11,80. Out again 25,09. Same pattern as with the April issue. Short trader short - from 11,80 down to approx 10,00 which is a support level. Technically there is now set a double bottom at approx 10 and the rise now points towards 13,50 some say about the technicals. I am an amateur there.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
35 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- 7 min sittenStay TunedNow you are probably looking to provoke "the phantom" on the forum here🫣🤣 Fingers crossed, some lose their breath from such☠️🤣 I am popping popcorn🍿🍿
- ·29 min sittenWe are just about in the most exciting and critical period for Circio, so it is probably not surprising that the stock does not dip like we see among several other biotechs right now (mostly due to the ten-year yield?). I believe the yield can speed up deals due to fear of missing out in the field, but that it can also go the other way. The only thing that matters now in my opinion is data releases which most likely will come on 27 October (ESGCT), and possibly in November. Conferences are not price-driving in themselves as long as they do not coincide with new data or a new deal. When in vivo in CNS is available, and if good data, we will hopefully soon see an up-front with BF. Then we will in that case guaranteed see a repricing. That is supposedly predicted to come at the end of '26 or sometime in H1 '27 (if everything goes according to plan). Car-t data will be price-driving, eye and heart as well, but everything still takes time, and 2027 could be the year things happen. And we can also hope for a positive surprise in addition to what we know and can relate to (not acquisitions, but deals). I believe a little patience will pay off anyway. That is if this goes the way most of us think. Please correct me. Go Circio🥳
- ·31 min sittenRegarding the use of the 200 million. - The delivery issues were identified long before September. The Acuitas partnership was announced as early as 15 April. The September share issue therefore provides financing to continue and expand an existing strategy. - The 200 million is also research capital. The funds will finance testing and selection of DNA vectors and delivery technology, as well as secure access to what works best. The entire amount is not an acquisition reserve. - A license can be the most important transaction. Circio does not need to own the supplier if the agreement grants sufficient commercial rights to the technology. The value will depend on, among other things, applications, potential exclusivity, sublicensing, and future payments. The most interesting question is therefore what rights Circio can secure. If the company combines circVec with a suitable DNA vector and good T-cell delivery, documents the function and secures attractive rights, it can provide a more complete offering to future industrial partners. Phoenix fits well into this strategy.
- 50 min sittenShorters still here? Where i can see them?They are not shorting now. The last short became visible/set 15.09 the same date as the issue came at 11,80. Out again 25,09. Same pattern as with the April issue. Short trader short - from 11,80 down to approx 10,00 which is a support level. Technically there is now set a double bottom at approx 10 and the rise now points towards 13,50 some say about the technicals. I am an amateur there.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 44 | - | - | ||
| 7 000 | - | - | ||
| 233 | - | - | ||
| 1 200 | - | - | ||
| 1 200 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
35 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- 7 min sittenStay TunedNow you are probably looking to provoke "the phantom" on the forum here🫣🤣 Fingers crossed, some lose their breath from such☠️🤣 I am popping popcorn🍿🍿
- ·29 min sittenWe are just about in the most exciting and critical period for Circio, so it is probably not surprising that the stock does not dip like we see among several other biotechs right now (mostly due to the ten-year yield?). I believe the yield can speed up deals due to fear of missing out in the field, but that it can also go the other way. The only thing that matters now in my opinion is data releases which most likely will come on 27 October (ESGCT), and possibly in November. Conferences are not price-driving in themselves as long as they do not coincide with new data or a new deal. When in vivo in CNS is available, and if good data, we will hopefully soon see an up-front with BF. Then we will in that case guaranteed see a repricing. That is supposedly predicted to come at the end of '26 or sometime in H1 '27 (if everything goes according to plan). Car-t data will be price-driving, eye and heart as well, but everything still takes time, and 2027 could be the year things happen. And we can also hope for a positive surprise in addition to what we know and can relate to (not acquisitions, but deals). I believe a little patience will pay off anyway. That is if this goes the way most of us think. Please correct me. Go Circio🥳
- ·31 min sittenRegarding the use of the 200 million. - The delivery issues were identified long before September. The Acuitas partnership was announced as early as 15 April. The September share issue therefore provides financing to continue and expand an existing strategy. - The 200 million is also research capital. The funds will finance testing and selection of DNA vectors and delivery technology, as well as secure access to what works best. The entire amount is not an acquisition reserve. - A license can be the most important transaction. Circio does not need to own the supplier if the agreement grants sufficient commercial rights to the technology. The value will depend on, among other things, applications, potential exclusivity, sublicensing, and future payments. The most interesting question is therefore what rights Circio can secure. If the company combines circVec with a suitable DNA vector and good T-cell delivery, documents the function and secures attractive rights, it can provide a more complete offering to future industrial partners. Phoenix fits well into this strategy.
- 50 min sittenShorters still here? Where i can see them?They are not shorting now. The last short became visible/set 15.09 the same date as the issue came at 11,80. Out again 25,09. Same pattern as with the April issue. Short trader short - from 11,80 down to approx 10,00 which is a support level. Technically there is now set a double bottom at approx 10 and the rise now points towards 13,50 some say about the technicals. I am an amateur there.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 44 | - | - | ||
| 7 000 | - | - | ||
| 233 | - | - | ||
| 1 200 | - | - | ||
| 1 200 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt